Patent intelligence · US
US 2025120959
NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE
NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE
Patent details — US 2025120959
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 17, 2025
- Expiration
- Apr 12, 2045
- Applicant
- BIOPROJET PHARMA [FR]
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 4453 A I, A61K/31335
Quick answer
US 2025120959 (NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Apr 17, 2025. Expires Apr 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOPROJET PHARMA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 4453 A I, A61K/31335, A61K/314453, A61K/92009
More from BIOPROJET PHARMA [FR]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2025120959?
US 2025120959 (NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Apr 17, 2025. Expires Apr 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2025120959?
BIOPROJET PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 2025120959 expire?
Our index shows an expiration date of Apr 12, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.